• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Thromboembolism - Pipeline Review, H2 2012 Product Image

Thromboembolism - Pipeline Review, H2 2012

  • Published: November 2012
  • 129 pages
  • Global Markets Direct

Thromboembolism – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Thromboembolism - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Thromboembolism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thromboembolism. Thromboembolism - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Thromboembolism.
- A review of the Thromboembolism products under development by companies and universities/research institutes based READ MORE >

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Thromboembolism Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Thromboembolism 11
Thromboembolism Therapeutics under Development by Companies 13
Thromboembolism Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Pre-Clinical Stage Products 21
Comparative Analysis 21
Thromboembolism Therapeutics – Products under Development by Companies 22
Thromboembolism Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Thromboembolism Therapeutics Development 24
Bristol-Myers Squibb Company 24
Sanofi-Aventis 25
Daiichi Sankyo Company, Ltd 26
Generex Biotechnology Corporation 27
BioLineRx, Ltd. 28
Bayer AG 29
ARYx Therapeutics 30
Portola Pharmaceuticals, Inc. 31
Emisphere Technologies, Inc. 32
Merrion Pharmaceuticals Plc 33
Cristalia Produtos Quimicos Farmaceuticos Ltda. 34
Endotis Pharma 35
Regado Biosciences. 36
Thrombotargets Corporation 37
Synthon Pharmaceuticals, Inc. 38
Diakron Pharmaceuticals, Inc. 39
Thromboembolism – Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
edoxaban - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
edoxaban - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
apixaban - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
betrixaban - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
semuloparin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
semuloparin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
rivaroxaban - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
rivaroxaban - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
tecarfarin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BL-5030 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
TT-105 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
fondaparinux sodium - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BLX-155 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Elaprin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DP-4088 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
REG2 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ardeparin sodium - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
dalteparin sodium - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
alteplase - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
fondaparinux sodium - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
bivalirudin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
aspirin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
enoxaparin sodium - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Bovine heparin - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
warfarin sodium - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
dalteparin sodium - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
fondaparinux sodium - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ardeparin sodium - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
aspirin - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
sodium enoxaparin - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
prednisone - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
enoxaparin sodium - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
rosuvastatin calcium - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
rivaroxaban - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Thromboembolism Therapeutics – Drug Profile Updates 91
Thromboembolism Therapeutics – Discontinued Products 116
Thromboembolism Therapeutics - Dormant Products 117
Thromboembolism – Product Development Milestones 118
Featured News & Press Releases 118
Nov 05, 2012: Boehringer Ingelheim Announces Development Of Antidote May Expand Range Of Methods To Reverse Anticoagulant Effect Of Pradaxa During Emergency Situations 118
Nov 02, 2012: FDA Mini-Sentinel Assessment Reinforces Safety Data Of Boehringer Ingelheim's Pradaxa 119
Nov 02, 2012: Janssen Pharma Announces Xarelto Obtains FDA Approval To Treat Deep Vein Thrombosis And Pulmonary Embolism 120
Nov 01, 2012: Portola, Bristol-Myers Squibb And Pfizer Sign Clinical Collaboration Agreement To Study Eliquis 121
Oct 25, 2012: Daiichi Sankyo Completes Enrolment In Hokusai-VTE Phase III Study Of Edoxaban For Treatment And Prevention Of Recurrence Of VTE 121
Oct 25, 2012: Daiichi Sankyo Completes Enrolment In Hokusai-VTE Phase III Study Of Edoxaban For Treatment And Prevention Of Recurrence Of VTE 122
Oct 19, 2012: Bayer Pharma Receives CHMP Positive Opinion For Xarelto For Treatment Of Pulmonary Embolism And Prevention Of Recurrent Deep Vein Thrombosis 123
Oct 01, 2012: Bristol-Myers Squibb And Pfizer Announce Eliquis Demonstrates Better Results Than Warfarin In Patients With Atrial Fibrillation At Varying Risk For Stroke And Bleeding 124
Sep 26, 2012: Bristol-Myers Squibb And Pfizer Announce FDA Acknowledges Receipt Of Resubmission Of Eliquis NDA And Grants New PDUFA Date 126
Jul 25, 2012: NICE Recommends Bayer's Xarelto For Treatment Of Blood Clots 126
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 129
Disclaimer 129

List of Tables
Number of Products Under Development for Thromboembolism, H2 2012 11
Products under Development for Thromboembolism – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 23
Bristol-Myers Squibb Company, H2 2012 24
Sanofi-Aventis, H2 2012 25
Daiichi Sankyo Company, Ltd, H2 2012 26
Generex Biotechnology Corporation, H2 2012 27
BioLineRx, Ltd., H2 2012 28
Bayer AG, H2 2012 29
ARYx Therapeutics, H2 2012 30
Portola Pharmaceuticals, Inc., H2 2012 31
Emisphere Technologies, Inc., H2 2012 32
Merrion Pharmaceuticals Plc, H2 2012 33
Cristalia Produtos Quimicos Farmaceuticos Ltda., H2 2012 34
Endotis Pharma, H2 2012 35
Regado Biosciences., H2 2012 36
Thrombotargets Corporation, H2 2012 37
Synthon Pharmaceuticals, Inc., H2 2012 38
Diakron Pharmaceuticals, Inc., H2 2012 39
Assessment by Monotherapy Products, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 44
Thromboembolism Therapeutics – Drug Profile Updates 91
Thromboembolism Therapeutics – Discontinued Products 116
Thromboembolism Therapeutics – Dormant Products 117

List of Figures
Number of Products under Development for Thromboembolism, H2 2012 11
Products under Development for Thromboembolism – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 40
Assessment by Route of Administration, H2 2012 41
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Molecule Type, H2 2012 43
Assessment by Stage and Molecule Type, H2 2012 44

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos